NANTES, France & PARIS, France I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, will present in an oral session preclinical studies results for Effi-DEM, a new generation checkpoint inhibitor targeting Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich, November 16th to 18th, 2016).
Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations, will present and comment all of the data from its preclinical studies conducted with Effi-DEM both in vivo and in vitro and in various cancer models.
Effi-DEM, a new generation checkpoint inhibitor specifically targeting the SIRP- α receptor on the strategic SIRP-α/CD47 pathway, has the potential to transform suppressor myeloid and macrophage cells in non-suppressive cells, thereby inducing a reactivation of the immune response, an anti-tumor impact and an immune memory.
SIRP-α is a receptor strongly expressed by Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is CD47. Suppressor immune cells MDSC and TAM play a key role in tumor growth of inflammatory cancers.
Effi-DEM has shown to be effective in various aggressive cancer models with encouraging preclinical results, both in monotherapy and in therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and anti-CD137 (4-1BB), activators of the T-cell response. Significant efficacy and survival increase data were demonstrated in hepatocarcinoma, melanoma and triple negative breast cancer models.
“These preclinical results validate the therapeutic potential of our new generation checkpoint inhibitor Effi-DEM in immuno-oncology, and show how the product enhances immune response by targeting novel checkpoint SIRP-α/CD 47 pathway. OSE Immunotherapeutics is at the forefront of this new immuno-oncology area and clearly focuses in developing such an innovative product”, commented Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.
Details of the presentation are as follows:
Title: Selective Targeting of The SIRP-α Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages
Date/Time: Thursday, November 17, 2016, 10:30am CET
Location: Maritim Hotel München, Goethestraße 7, 80336 Munich, Germany
These preclinical data will also be presented in an abstract at the Annual World Gene Convention-2016 (WGC-2016), which will be held during November 3-5, 2016 in Shanghai, China.
About ICI (IMMUNE CHECKPOINT INHIBITORS) EUROPE
ICI Europe is a forum dedicated to immune checkpoint inhibitors. It focuses specifically on the preclinical, translational and clinical challenges that drug developers face in advancing more checkpoint inhibitors onto the market. Combining data driven case studies with interactive experience sharing sessions, its program provides cutting edge insights into novel checkpoint pathways, more predictive preclinical models, the optimal combination strategies, patient stratification biomarkers and emerging clinical trial data.
ABOUT WGC (ANNUAL WORLD GENE CONVENTION)
WGC-2016 features a very strong technical program, mainly focused on breakthroughs in DNA and RNA research, advances of genomics & genetics, the frontier research of life sciences. It aims to provide a platform for all experts from academia, industry and national labs to discuss latest hot researches and achievements.
ABOUT OSE IMMUNOTHERAPEUTICS
Our ambition is to become a world leader in activation and regulation immunotherapies
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:
- Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology – currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US – Orphan Status in the US – registration expected in 2019 – a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 – the product is also considered in other cancer indications.
- FR104, CD28-antagonist in immunotherapy – Phase 1 trial completed – targets autoimmune diseases and transplantation – licensed to J&J to pursue clinical development
- Effi-7, interleukin receptor 7 antagonist – in preclinical development for inflammatory bowel diseases and other autoimmune diseases
- Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor on the strategic SIRP-α/CD47 pathway – in preclinical development for immuno-oncology
- R&D: candidates targeting new receptors in immuno-oncology
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
SOURCE: OSE Immunotherapeutics
Post Views: 72
NANTES, France & PARIS, France I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, will present in an oral session preclinical studies results for Effi-DEM, a new generation checkpoint inhibitor targeting Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich, November 16th to 18th, 2016).
Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations, will present and comment all of the data from its preclinical studies conducted with Effi-DEM both in vivo and in vitro and in various cancer models.
Effi-DEM, a new generation checkpoint inhibitor specifically targeting the SIRP- α receptor on the strategic SIRP-α/CD47 pathway, has the potential to transform suppressor myeloid and macrophage cells in non-suppressive cells, thereby inducing a reactivation of the immune response, an anti-tumor impact and an immune memory.
SIRP-α is a receptor strongly expressed by Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is CD47. Suppressor immune cells MDSC and TAM play a key role in tumor growth of inflammatory cancers.
Effi-DEM has shown to be effective in various aggressive cancer models with encouraging preclinical results, both in monotherapy and in therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and anti-CD137 (4-1BB), activators of the T-cell response. Significant efficacy and survival increase data were demonstrated in hepatocarcinoma, melanoma and triple negative breast cancer models.
“These preclinical results validate the therapeutic potential of our new generation checkpoint inhibitor Effi-DEM in immuno-oncology, and show how the product enhances immune response by targeting novel checkpoint SIRP-α/CD 47 pathway. OSE Immunotherapeutics is at the forefront of this new immuno-oncology area and clearly focuses in developing such an innovative product”, commented Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.
Details of the presentation are as follows:
Title: Selective Targeting of The SIRP-α Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages
Date/Time: Thursday, November 17, 2016, 10:30am CET
Location: Maritim Hotel München, Goethestraße 7, 80336 Munich, Germany
These preclinical data will also be presented in an abstract at the Annual World Gene Convention-2016 (WGC-2016), which will be held during November 3-5, 2016 in Shanghai, China.
About ICI (IMMUNE CHECKPOINT INHIBITORS) EUROPE
ICI Europe is a forum dedicated to immune checkpoint inhibitors. It focuses specifically on the preclinical, translational and clinical challenges that drug developers face in advancing more checkpoint inhibitors onto the market. Combining data driven case studies with interactive experience sharing sessions, its program provides cutting edge insights into novel checkpoint pathways, more predictive preclinical models, the optimal combination strategies, patient stratification biomarkers and emerging clinical trial data.
ABOUT WGC (ANNUAL WORLD GENE CONVENTION)
WGC-2016 features a very strong technical program, mainly focused on breakthroughs in DNA and RNA research, advances of genomics & genetics, the frontier research of life sciences. It aims to provide a platform for all experts from academia, industry and national labs to discuss latest hot researches and achievements.
ABOUT OSE IMMUNOTHERAPEUTICS
Our ambition is to become a world leader in activation and regulation immunotherapies
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:
- Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology – currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US – Orphan Status in the US – registration expected in 2019 – a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 – the product is also considered in other cancer indications.
- FR104, CD28-antagonist in immunotherapy – Phase 1 trial completed – targets autoimmune diseases and transplantation – licensed to J&J to pursue clinical development
- Effi-7, interleukin receptor 7 antagonist – in preclinical development for inflammatory bowel diseases and other autoimmune diseases
- Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor on the strategic SIRP-α/CD47 pathway – in preclinical development for immuno-oncology
- R&D: candidates targeting new receptors in immuno-oncology
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
SOURCE: OSE Immunotherapeutics
Post Views: 72
